Where Food Comes From, Inc. (WFCF) Q4 2024 Earnings Call Transcript — Neutral
WFCF Seeking Alpha — February 21, 2025Where Food Comes From, Inc. (NASDAQ:WFCF ) Q4 2024 Results Conference Call February 20, 2025 12:00 PM ET Company Participants Jay Pfeiffer - Investor Relations John Saunders - Chief Executive Officer Leann Saunders - President Dannette Henning - Chief Financial Officer Operator Welcome to Where Food Comes From 2024 Year-End Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.

Equinor plans sale of onshore assets in Argentina, local news report says — Neutral
EQNR Reuters — February 21, 2025Norwegian oil and gas firm Equinor is looking to sell its onshore assets in Argentina's Vaca Muerta region, the Mas Energia online publication reported, citing unnamed sources.

Travere Therapeutics, Inc. (TVTX) Q4 2024 Earnings Call Transcript — Neutral
TVTX Seeking Alpha — February 21, 2025Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Victoria Prescott - Manager of Investor Relations Eric Dube - President and CEO Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - CFO William Rote - Senior Vice President of Research & Development Conference Call Participants Malcolm Kuno - JPMorgan Vamil Divan - Guggenheim Securities Joseph Schwartz - Leerink Partners Liisa Bayko - Evercore ISI Yigal Nochomovitz - Citigroup Prakhar Agrawal - Cantor Fitzgerald Fadi Ahman - Wells Fargo Gregory Harrison - Scotiabank Jason Zemansky - …

Oceaneering's Q4 Earnings Miss Estimates, Revenues Beat — Negative
OII Zacks Investment Research — February 21, 2025OII expects net income to be between $160 million and $190 million, with consolidated EBITDA between $380 million and $430 million for 2025.

Cleveland-Cliffs to Post Q4 Earnings: What's in Store for the Stock? — Neutral
CLF Zacks Investment Research — February 21, 2025While CLF is expected to have benefited from actions to reduce costs, lower prices and weaker volumes are likely to have weighed on its Q4 performance.

Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus — Positive
KRYS Seeking Alpha — February 21, 2025Krystal Biotech's VYJUVEK shows strong growth, with 2025 sales expected to exceed $1B, bolstered by launches in the EU and Japan. Q4 earnings beat EPS expectations but slightly missed revenue forecasts; however, management's 2025 outlook coming catalysts drove a strong rally in shares. Key 2025 catalysts include VYJUVEK's EU and Japan launches, Phase 3 ocular DEB results, and progress in CF and lung gene therapy.

Arbor Realty Trust Reports Fourth Quarter and Full Year 2024 Results and Declares Dividend of $0.43 per Share — Neutral
ABR GlobeNewsWire — February 21, 2025Fourth Quarter Highlights: GAAP net income of $0.32 and distributable earnings of $0.40, per diluted common share1 Declares cash dividend on common stock of $0.43 per share Agency loan originations of $1.38 billion and a servicing portfolio of ~$33.47 billion Structured loan originations of $684.3 million, runoff of $900.6 million, and a portfolio of ~$11.30 billion Issued $100.0 million of 9.00% senior notes due 2027 Full Year Highlights: GAAP net income of $1.18 and distributable earnings of $1.74 per diluted common share1 Agency servicing portfolio growth of 8% from loan originations of $4.47 billion Successfully delevered the Company 30% from …

3 Top Warren Buffett Stocks to Buy Right Now — Positive
AMZN DPZ KO The Motley Fool — February 21, 2025Warren Buffett has an unrivaled track record of creating piles of money. From 1965 through 2023, Buffett's knack for spotting value that Wall Street overlooks has grown the value of Berkshire Hathaway stock by 4,384,748%.

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025 — Neutral
ADTX Business Wire — February 21, 2025MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. (“Pearsanta”), has engaged Dominari Securities LLC as lead underwriter for Pearsanta's planned initial public offering (IPO). The proposed IPO, advised by Dominari Securities, is intended to support Pearsanta's U.S. and international commercial launch efforts and.

Northern's Q4 Earnings Lag Estimates, Revenues Increase Y/Y — Negative
NOG Zacks Investment Research — February 21, 2025NOG expects annual oil production in the range of 75,000-79,000 barrels per day and total production in the band of 130,000-135,000 Boe/d for 2025.

PagSeguro Digital Ltd. (PAGS) Q4 Earnings and Revenues Beat Estimates — Positive
PAGS Zacks Investment Research — February 21, 2025PagSeguro Digital Ltd. (PAGS) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.29 per share.

US securities regulator to drop lawsuit against Coinbase, exchange says — Positive
COIN Reuters — February 21, 2025Coinbase said on Friday the U.S. securities regulator planned to withdraw its lawsuit against the crypto exchange, ending a contentious years-long legal battle once considered existential for the trading platform and the broader sector.

Shares of Palantir Technologies Inc. NASDAQ: PLTR are down 17% in two trading sessions. For much of the last 18 months, Palantir has been like a boxer who continues to have opponents throw punches, none of which land with any effect.

Shares of AppLovin, Corp. (APP), which operates a marketing platform and makes mobile apps, are up 685% in a year.

Butterfly Network to Participate at the TD Cowen 45th Annual Health Care Conference on March 3, 2025 — Neutral
BFLY Business Wire — February 21, 2025NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)---- $BFLY #POCUS--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”) a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that it will present and host one-on-one investor meetings at the TD Cowen 45th Annual Health Care Conference in Boston on March 3, 2025. Heather Getz, Executive Vice President & Chief Financial and Operations Officer will host one-on-one meetings and will present a business o.

2 S&P 500 ETFs for Growth and Leverage in a Hot Market — Neutral
SPUU SPYG MarketBeat — February 21, 2025To put it mildly, it's been a very good couple of years for the S&P. Following a tepid 2022, the banner S&P 500 index has accelerated growth from 2023 into 2024.

Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite? — Neutral
RXRX MarketBeat — February 21, 2025Recursion Pharmaceuticals' NASDAQ: RXRX stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence (AI) chip giant NVIDIA NASDAQ: NVDA. A recent SEC filing showed NVIDIA reshuffling its AI investment portfolio, and while it trimmed its holdings in several AI ventures, it notably maintained its stake in Recursion Pharmaceuticals.

GameStop CEO Ups Alibaba Bet to $1 Billion. Why Earnings Wowed the Street. — Positive
BABA GME Barrons — February 21, 2025The e-commerce stock has started 2025 on a tear, with investors betting that China's faltering economy will rebound.

Gold Mining ETF (GDXJ) Hits New 52-Week High — Positive
GDXJ Zacks Investment Research — February 21, 2025For investors seeking momentum, VanEck Junior Gold Miners ETF GDXJ is probably on the radar. The fund just hit a 52-week high and is up about 80% from its 52-week low price of $31.00/share.

NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program — Neutral
NKGN GlobeNewsWire — February 21, 2025NKGen takes a meaningful step towards potential treatment for frontotemporal dementia (“FTD”) patients with limited treatment options. NKGen takes a meaningful step towards potential treatment for frontotemporal dementia (“FTD”) patients with limited treatment options.
